<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36239">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02634788</url>
  </required_header>
  <id_info>
    <org_study_id>INS005-15-062</org_study_id>
    <nct_id>NCT02634788</nct_id>
  </id_info>
  <brief_title>Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain</brief_title>
  <official_title>A Phase 3, Randomized, Double Blind, Multiple Dose, Parallel Group, Placebo Controlled Study of Buprenorphine Sublingual Spray (0.5 mg TID, 0.25 mg TID, and 0.125 mg TID) for the Treatment of Moderate to Severe Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>INSYS Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>INSYS Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to evaluate analgesic efficacy of Buprenorphine
      Sublingual Spray compared with placebo in subjects with postoperative pain after
      bunionectomy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numeric rating scale (NRS) summed pain intensity difference (SPID) over 0 to 48 hours (NRS SPID 48) after Time 0</measure>
    <time_frame>over 0 to 48 hours after Time 0</time_frame>
    <description>NRS SPID is calculated as a time weighted average of pain rated by the participant from 0 to 10 (&quot;no pain&quot; to &quot;worst pain imaginable&quot;)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NRS pain intensity difference (NRS PID) at each categorical time point after Time 0</measure>
    <time_frame>within 48 hours</time_frame>
    <description>Categories: 4 hours, 8 hours, 24 hours, 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NRS pain intensity score at each scheduled time point</measure>
    <time_frame>within 48 hours</time_frame>
    <description>Categories: Baseline, 5, 15, 30, and 45 minutes, and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 12, 16, 20, 24, 32, 40, and 48 hours, as well as immediately before each use of rescue analgesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NRS SPID after Time 0</measure>
    <time_frame>within 24 hours</time_frame>
    <description>Categories: over 0 to 4 hours (NRS SPID 4), over 0 to 8 hours (NRS SPID 8), and over 0 to 24 hours (NRS SPID 24)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total pain relief (TOTPAR) after Time 0</measure>
    <time_frame>within 48 hours</time_frame>
    <description>Categories: over 0 to 4 hours (TOTPAR 4), over 0 to 8 hours (TOTPAR 8), over 0 to 24 hours (TOTPAR 24), and over 0 to 48 hours (TOTPAR 48)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of analgesia</measure>
    <time_frame>within 48 hours</time_frame>
    <description>Measured as time to perceptible pain relief confirmed by meaningful pain relief using the 2-stopwatch method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain relief at each scheduled time point after Time 0 (first dose of study medication)</measure>
    <time_frame>within 48 hours</time_frame>
    <description>Pain relief is determined on a 5-point categorical scale where 0=none, 1=a little, 2=some, 3=a lot, 4=complete, at 5, 15, 30, and 45 minutes, and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 12, 16, 20, 24, 32, 40, and 48 hours, as well as immediately before each use of rescue analgesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak pain relief from Time 0 (first dose of study medication)</measure>
    <time_frame>within 48 hours after Time 0</time_frame>
    <description>The highest level of pain relief achieved on a 5-point categorical scale where 0=none, 1=a little, 2=some, 3=a lot, 4=complete</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (minutes) to peak pain relief from Time 0 (first dose of study medication)</measure>
    <time_frame>within 48 hours after Time 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (minutes) to first perceptible pain relief from Time 0 (first dose of study medication)</measure>
    <time_frame>within 48 hours after Time 0</time_frame>
    <description>Time to perceptible and meaningful pain relief will be evaluated using the 2-stopwatch method (after the first dose only).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (minutes) to meaningful pain relief from Time 0 (first dose of study medication)</measure>
    <time_frame>within 48 hours after Time 0</time_frame>
    <description>Time to perceptible and meaningful pain relief will be evaluated using the 2-stopwatch method (after the first dose only).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants using rescue medication</measure>
    <time_frame>within 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (hours) to first use of rescue medication (duration of analgesia)</measure>
    <time_frame>within 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants using rescue analgesia over 0 to 24 hours and over 0 to 48 hours</measure>
    <time_frame>within 48 hours</time_frame>
    <description>Categories: over 0 to 24 hours; over 0 to 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant global evaluation of study drug</measure>
    <time_frame>within 48 hours</time_frame>
    <description>Participants provide a global evaluation of study drug on a 5-point categorical scale where 0 = poor, 1 = fair, 2 = good, 3 = very good, and 4 = excellent.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">322</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Low Dose Buprenorphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose buprenorphine delivered via sublingual spray three times daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium Dose Buprenorphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium dose buprenorphine delivered via sublingual spray three times daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Buprenorphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose buprenorphine delivered via sublingual spray three times daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo delivered via sublingual spray three times daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>Buprenorphine delivered via sublingual spray</description>
    <arm_group_label>Low Dose Buprenorphine</arm_group_label>
    <arm_group_label>Medium Dose Buprenorphine</arm_group_label>
    <arm_group_label>High Dose Buprenorphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo delivered via sublingual spray</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets protocol-specified criteria for qualification and contraception

          -  Willing and able to remain confined in the study unit for the entire duration of each
             treatment period and comply with restrictions related food, drink and medications

          -  Voluntarily consents to participate and provides written informed consent prior to
             any protocol-specific procedures

        Exclusion Criteria:

          -  History or current use of over-the-counter medications, dietary supplements, or drugs
             (including nicotine and alcohol) outside protocol-specified parameters

          -  Signs, symptoms or history of any condition that, per protocol or in the opinion of
             the investigator, might compromise:

               1. the safety or well-being of the participant or study staff;

               2. the safety or well-being of the participant's offspring (such as through
                  pregnancy or breast-feeding);

               3. the analysis of results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni DeCastro</last_name>
    <role>Study Director</role>
    <affiliation>INSYS Therapeutics Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Research Group</name>
      <address>
        <city>Pasadena</city>
        <state>Maryland</state>
        <zip>21122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 28, 2016</lastchanged_date>
  <firstreceived_date>December 16, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post-Surgical Pain</keyword>
  <keyword>Bunionectomy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
